V160
Biological
Merck Sharp & Dohme Corporation
Total Payments
$14.9M
Transactions
9,372
Doctors
40
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $3.6M | 3,123 | 6 |
| 2019 | $6.6M | 5,092 | 10 |
| 2018 | $4.5M | 1,132 | 34 |
| 2017 | $78,821 | 25 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.7M | 8,991 | 99.3% |
| Consulting Fee | $61,836 | 42 | 0.4% |
| Travel and Lodging | $33,098 | 127 | 0.2% |
| Food and Beverage | $10,426 | 211 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,030 | 1 | 0.0% |
Payments by Type
Research
$14.7M
8,991 transactions
General
$106,390
381 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age | Merck Sharp & Dohme Corporation | $13.5M | 0 |
| A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose- Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of the Human Cytomegalovirus Vaccine V160 in Healthy Adults | Merck Sharp & Dohme Corporation | $479,439 | 0 |
| Risk Factors and Virological Correlates of Non-Primary Maternal HCMV Infections | Merck Sharp & Dohme Corporation | $384,252 | 0 |
| Maximizing Outcome Measures for CMV VP160 Vaccine | Merck Sharp & Dohme Corporation | $133,650 | 0 |
| Immune markers of placental transmission of congenital CMV | Merck Sharp & Dohme Corporation | $97,200 | 0 |
| Improved CMV Dried Bloods Spot PCR for universal CMV screening through Early Check | Merck Sharp & Dohme Corporation | $61,496 | 0 |
| Inhibition of Mycobacterium abscessus by ceftolozane-tazobactam and imipenem-relebactam | Merck Sharp & Dohme Corporation | $60,750 | 0 |
| Comprehensive Analysis of CMV-specific T cells in Human Subjects Receiving a Replication-defective Human Cytomegalovirus Vaccine | Merck Sharp & Dohme Corporation | $57,055 | 0 |
Top Doctors Receiving Payments for V160
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Galveston, TX | $14.7M | 8,991 |
| , MD | Pediatrics | Richmond, VA | $14,548 | 14 |
| , MD | Emergency Medicine | Birmingham, AL | $11,167 | 10 |
| , MD MPH | Infectious Disease | Seattle, WA | $8,118 | 7 |
| , M.D | Pediatric Infectious Diseases | Cincinnati, OH | $8,096 | 20 |
| , M.D | Internal Medicine | Baltimore, MD | $5,944 | 10 |
| , MD | Pediatric Infectious Diseases | Houston, TX | $4,275 | 2 |
| , MD PHD | Pediatrics | Aurora, CO | $4,275 | 2 |
| , M.D | Infectious Disease | Worcester, MA | $4,275 | 2 |
| , MD | Pediatrics | Minneapolis, MN | $4,275 | 2 |
| , MD | Orthopaedic Surgery | Spokane, WA | $2,585 | 12 |
| , M.D | Specialist | Durham, NC | $2,250 | 4 |
| , M.D | Gastroenterology | Los Angeles, CA | $2,057 | 9 |
| , MD | Obstetrics & Gynecology | Beverly Hills, CA | $1,876 | 13 |
| , MD | Allergy & Immunology | Upland, CA | $1,751 | 14 |
| , MD | Endocrinology, Diabetes & Metabolism | Pleasanton, CA | $1,690 | 12 |
| , M.D | Internal Medicine | Chandler, AZ | $1,532 | 13 |
| , MD | Rheumatology | Austin, TX | $1,462 | 11 |
| , MD | Pediatrics | Birmingham, AL | $1,348 | 11 |
| , D.O | Family Medicine | Jacksonville, FL | $1,297 | 11 |
| , MD | Pediatrics | Shreveport, LA | $1,272 | 11 |
| , M.D | Emergency Medicine | Bedford, OH | $1,267 | 11 |
| , MD | Adolescent Medicine | Galveston, TX | $1,257 | 11 |
| , MD | Family Medicine | Hialeah, FL | $1,241 | 10 |
| , MD | Pediatrics | South Euclid, OH | $1,239 | 9 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $14.9M
- Total Doctors 40
- Transactions 9,372
About V160
V160 is a biological associated with $14.9M in payments to 40 healthcare providers, recorded across 9,372 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $3.6M was paid across 3,123 transactions to 6 doctors.
The most common payment nature for V160 is "Unspecified" ($14.7M, 99.3% of total).
V160 is associated with 8 research studies, including "Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age" ($13.5M).